OpenCancer.ai provides free, AI-powered cancer care answers reviewed by PhD scientists, helping patients and caregivers understand diagnoses, treatments, and clinical trials. The platform reads uploaded medical records to deliver personalized, plain-English responses grounded in NCCN guidelines, with optional expert case reviews. No signup is required, and patient data is never sold or shared without consent.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer patients and caregivers often struggle to understand complex medical terminology, treatment options, and clinical trial opportunities, especially when facing urgent decisions. Generic AI chatbots lack access to individual patient records, and expert consultations are expensive or inaccessible, leaving patients without clear, personalized guidance between doctor visits.
Solution
OpenCancer.ai offers a free, no-signup platform where patients can ask plain-English questions about their diagnosis, treatment, and trials. Users can upload pathology reports, imaging results, and other records, enabling the AI to generate answers specific to their case rather than general cancer information. Every response is grounded in NCCN guidelines and includes visible sources, and when patients want human input, real PhD cancer scientists can review the full case and provide expert recommendations. The platform also offers free second-opinion case reviews, a service that typically costs over $2,000 elsewhere, helping patients identify questions and options to discuss with their oncologist.
Target Audience
Primary users are cancer patients and their caregivers who need clear, personalized answers about their diagnosis, treatment options, and clinical trials, as well as those seeking a free expert second opinion on their care plan.
Features
- AI-powered answers that read uploaded medical records (pathology reports, CT scans, etc.) to personalize every response
- Plain-English explanations of diagnosis, treatment options, and clinical trial eligibility
- Free expert case reviews by PhD cancer scientists, covering 50+ cancer types from breast and lung to rare leukemias and sarcomas
- All answers cite NCCN guidelines with visible sources for verification
- Strict privacy controls: records are never shared without explicit patient sign-off, and no data is sold
- No signup or payment required for any feature, including scientist-reviewed second opinions